» Articles » PMID: 8999970

Activities of the Microtubule-stabilizing Agents Epothilones A and B with Purified Tubulin and in Cells Resistant to Paclitaxel (Taxol(R))

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1997 Jan 24
PMID 8999970
Citations 110
Authors
Affiliations
Soon will be listed here.
Abstract

Epothilones A and B, natural products with minimal structural analogy to taxoids, have effects similar to those of paclitaxel (Taxol(R)) in cultured cells and on microtubule protein, but differ from paclitaxel in retaining activity in multidrug-resistant cells. We examined interactions of the epothilones with purified tubulin and additional cell lines, including a paclitaxel-resistant ovarian carcinoma line with an altered beta-tubulin. The epothilones, like paclitaxel, induced tubulin to form microtubules at low temperatures and without GTP and/or microtubule-associated proteins. The epothilones are competitive inhibitors of the binding of [3H]paclitaxel to tubulin polymers. The apparent Ki values for epothilones A and B were 1.4 and 0.7 microM by Hanes analysis and 0.6 and 0.4 microM by Dixon analysis. In the paclitaxel-sensitive human cell lines we examined, epothilone B had greater antiproliferative activity than epothilone A or paclitaxel, while epothilone A was usually less active than paclitaxel. A multidrug-resistant colon carcinoma line and the paclitaxel-resistant ovarian line retained sensitivity to the epothilones. With Potorous tridactylis kidney epithelial (PtK2) cells examined by indirect immunofluorescence, microtubule bundles appeared more rapidly following epothilone B treatment, and there were different proportions of various mitotic aberrations following treatment with different drugs.

Citing Articles

Evaluation of ixabepilone efficacy and tolerability in metastatic breast cancer.

Erciyestepe M, Ekinci O, Secmeler S, Selvi O, Ozturk A, Aydin O Medicine (Baltimore). 2025; 103(47):e40649.

PMID: 39809199 PMC: 11596583. DOI: 10.1097/MD.0000000000040649.


Utidelone-based therapy in advanced or metastatic solid tumors after failure of standard therapies: a prospective, multicenter, single-arm trial.

Qiao G, Liu Z, Ding H, Lu H, Lin F, Shi Y Am J Cancer Res. 2024; 14(9):4514-4522.

PMID: 39417192 PMC: 11477828. DOI: 10.62347/OLES9793.


PM534, an Optimized Target-Protein Interaction Strategy through the Colchicine Site of Tubulin.

Lucena-Agell D, Guillen M, Matesanz R, Alvarez-Bernad B, Hortiguela R, Aviles P J Med Chem. 2024; 67(4):2619-2630.

PMID: 38294341 PMC: 10895673. DOI: 10.1021/acs.jmedchem.3c01775.


Bioprocessing of Epothilone B from Aspergillus fumigatus under solid state fermentation: Antiproliferative activity, tubulin polymerization and cell cycle analysis.

El-Sayed A, Shindia A, Ammar H, Seadawy M, Khashana S BMC Microbiol. 2024; 24(1):43.

PMID: 38291363 PMC: 10829302. DOI: 10.1186/s12866-024-03184-w.


Diverse microtubule-targeted anticancer agents kill cells by inducing chromosome missegregation on multipolar spindles.

Zhou A, Tucker J, Scribano C, Lynch A, Carlsen C, Pop-Vicas S PLoS Biol. 2023; 21(10):e3002339.

PMID: 37883329 PMC: 10602348. DOI: 10.1371/journal.pbio.3002339.